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lncRNAs and latent HIV - search for novel targets for latency reversal
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Methods
• Worldwide 35 million people are HIV-infected
• HIV infection evolved from a deadly to a chronic disease 
• Current treatment can suppress HIV but not offer a cure
• Condemned to lifelong treatment due to a latent reservoir
HIV
Goal
• Study HIV latency & explore new treatment strategies
• Primary cell models for main reservoir of HIV: CD4 T cells
• Focus on lncRNAs in HIV latency and cure research
Problem
Results
• lncRNA discovery via total RNAseq, ribodepleted (4 biological replicates per model, Illumina Hiseq 2500, 30-50M reads per sample)
• Downstream analysis: Differential expression, ddPCR validation, pathway analysis and T cell subset analysis
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RP11-347C18.3, RP11-539L10.2, PVT1
Differential Expression: lncRNAs
Focus on PVT1
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• lncRNA contribute to HIV latency
• lncRNA linked to pathways for 
possible therapy
• PVT1 is prioritized candidate 
for further research
• Functional validation with 
targeted knockdown studies
are required
2 Pathways (Biocarta) P53 Detailed View
• Direct infection of activated cells
• Differentiated CD4 T memory cells
• Return to resting state (latent)
• Latent cell fraction: 5-10%
• Two step infection: cell spreading 
• Primary CD4 T cell pool 
• Resting cells
• Latent cell fraction: 5-10%
Conclusion
